Compare TECH & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TECH | EVR |
|---|---|---|
| Founded | 1976 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 11.7B |
| IPO Year | 1989 | 2006 |
| Metric | TECH | EVR |
|---|---|---|
| Price | $58.68 | $335.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $71.23 | ★ $326.56 |
| AVG Volume (30 Days) | ★ 1.7M | 339.3K |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | 0.55% | ★ 1.00% |
| EPS Growth | N/A | ★ 61.11 |
| EPS | 0.49 | ★ 12.55 |
| Revenue | $1,216,732,000.00 | ★ $3,542,875,000.00 |
| Revenue This Year | $2.33 | $25.39 |
| Revenue Next Year | $7.05 | $16.43 |
| P/E Ratio | $120.22 | ★ $26.86 |
| Revenue Growth | 3.85 | ★ 27.03 |
| 52 Week Low | $46.01 | $148.63 |
| 52 Week High | $79.28 | $364.42 |
| Indicator | TECH | EVR |
|---|---|---|
| Relative Strength Index (RSI) | 41.76 | 61.16 |
| Support Level | $58.75 | $319.69 |
| Resistance Level | $61.20 | $349.91 |
| Average True Range (ATR) | 2.02 | 10.83 |
| MACD | -0.49 | 2.97 |
| Stochastic Oscillator | 2.94 | 72.03 |
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. The firm operates globally with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.